Tryp Therapeutics Announces Significant Milestone in Its Clinical Trial Program for Trp-8803 (IV-inf

KELOWNA BC / ACCESSWIRE / January 8, 2024 / Tryp Therapeutics, Inc. ("Tryp" or the "Company") (CSE:TRYP)(OTCQB:TRYPF), a pioneering clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical ne...

Related Keywords

Michigan ,United States ,Massachusetts ,Australia ,Adelaide ,South Australia ,Australian ,Jim Gilligan ,Peter Molloy ,Australian Securities Exchange ,Administration In Concert ,Tryp Therapeutics Inc ,University Of Michigan ,Human Research Ethics Committee ,University Of Florida ,Tryp Therapeutics ,Dose Escalation Study ,Single Intravenous ,Healthy Adult Participants ,Chief Scientific Officer ,Abdominal Pain Related ,Irritable Bowel Syndrome ,Massachusetts General Hospital ,Institutional Review Board ,Pilot Study ,Oral Psilocybin ,Irritable Bowel ,Private Placement ,